Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10698614 | 0.98 | SIGMAR1 (0.63) | SIGMAR1CHRM5CHRM3ALDH1A1KMT2A | |
| SCHEMBL14369164 | 0.98 | SIGMAR1 (0.63) | SIGMAR1CHRM5CHRM3ALDH1A1KMT2A | |
| SCHEMBL1905216 | 0.85 | SIGMAR1 (0.71) | SIGMAR1CHRM5CHRM3ALDH1A1KMT2A | |
| SCHEMBL1900359 | 0.82 | SIGMAR1 (0.67) | SIGMAR1CHRM5CHRM3ALDH1A1KMT2A | |
| SCHEMBL19010425 | 0.82 | ALDH1A1 (0.61) | SIGMAR1CHRM5CHRM3ALDH1A1KMT2A | |
| SCHEMBL8023138 | 0.82 | ALDH1A1 (0.67) | SIGMAR1ALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10687011 | 0.81 | SIGMAR1 (0.65) | SIGMAR1CHRM5CHRM3ALDH1A1SMN1; SMN2 | |
| SCHEMBL8395095 | 0.81 | SIGMAR1 (0.65) | SIGMAR1CHRM5CHRM3ALDH1A1KMT2A | |
| SCHEMBL6632135 | 0.81 | SIGMAR1 (0.60) | SIGMAR1CHRM5CHRM3ALDH1A1KMT2A | |
| SCHEMBL255416 | 0.80 | CHRM5 (0.65) | SIGMAR1CHRM5CHRM3ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| CN-107001325-B | O-formamido benzamide compound and application thereof | 江苏中旗科技股份有限公司 | 2020-06-16 | — | — | CN | disclosed |
| CN-107001325-A | O-formamido benzamide compound and application thereof | 江苏中旗作物保护股份有限公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-3008055-B1 | TETRAZOLONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-3008055-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2014198592-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-18 | — | — | WO | disclosed |
| EP-1797062-B1 | ALKYNYL BASED DERVATIVES OF BENZOPHENONE AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-01-12 | — | — | EP | disclosed |
| EP-1874739-B1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
| EP-1963331-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | VCAM1, ICAM1, CD69 | SIGMAR1 1093/4885CHRM5 542/4885CHRM3 470/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | SIGMAR1 1391/4885CHRM5 143/4885CHRM3 74/4885 |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | TBXA2R, CYP11B2, NR1I2 | SIGMAR1 118/4885CHRM5 1255/4885CHRM3 1452/4885 |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | DMPK, PDXK, NIM1K | SIGMAR1 1834/4885CHRM5 245/4885CHRM3 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.